NCT00627588View on ClinicalTrials.gov

Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Parkinson's Disease
Interventions
BIOLOGICAL

ProSavin

ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine

BIOLOGICAL

ProSavin

ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine

Trial Locations (2)

Unknown

Henri Mondor Hospital, Paris

CB2 0QQ

Addenbrookes Hospital, Cambridge

Sponsors

Lead Sponsor

Oxford BioMedica
All Listed Sponsors
lead

Oxford BioMedica

INDUSTRY

NCT00627588 - Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease | Biotech Hunter | Biotech Hunter